

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 December 2024 (12.12.2024)



(10) International Publication Number
WO 2024/252010 A1

(51) International Patent Classification:

A61K 31/10 (2006.01) *A61K 45/06* (2006.01)
A61K 31/18 (2006.01) *A61P 19/00* (2006.01)
A61K 31/277 (2006.01) *A61P 19/02* (2006.01)
A61K 31/4418 (2006.01) *A61P 29/00* (2006.01)
A61K 31/445 (2006.01) *A61P 37/00* (2006.01)
A61K 39/00 (2006.01) *A61P 43/00* (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/EP2024/065836

(22) International Filing Date:

07 June 2024 (07.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2308547.5 08 June 2023 (08.06.2023) GB

(71) Applicant: **ISTESSO 2 LIMITED** [GB/GB]; 3 Pancras Square, Kings Cross, London NIC 4AG (GB).

(72) Inventors: **FOSTER, Martyn Leslie**; 45 Hope Road, Benfleet, Essex Essex SS7 5JQ (GB). **PATEL, Lisa**; 3 Pancras Square, Kings Cross, London Greater London NIC 4AG (GB).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TNF INHIBITOR COMBINATION THERAPIES

(57) Abstract: The invention provides combination therapies comprising TNF inhibitor compounds and mitochondrial complex I modulator (MCIM) compounds, which find utility in the medical field of inflammatory and progressive disorders such as RA, IBD, idiopathic pulmonary fibrosis, interstitial lung disease, and MS.

WO 2024/252010 A1